INVESTOR ALERT: Investigation of Galectin Therapeutics Inc. Announced by Glancy Binkow & Goldberg LLP

LOS ANGELES--(BUSINESS WIRE)--

Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Galectin Therapeutics Inc. (“Galectin” or the “Company”) GALT concerning possible violations of federal securities laws. The investigation focuses on certain statements issued by the Company concerning Galectin's business and financial prospects.

Please contact Casey Sadler, Esquire, at (888) 773-9224 or (310) 201-9150, or at shareholders@glancylaw.com to discuss this matter. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

Galectin, a development stage company, is engaged in the research and development of therapies for fibrotic disease and cancer. The investigation relates to the publication of a July 28, 2014, article that disclosed that the Company had hired a stock promotions firm to tout its securities. The investigation also relates to the Company's July 29, 2014, disclosure that its experimental drug GR-MD-02, which was being developed for the treatment of fatty liver disease, showed little difference from a placebo in its Phase 1 study. On this news, shares of Galectin declined $8.84 per share, or 60.80%, to close on July 29, 2014, at $5.70 per share, on unusually heavy volume.

If you purchased shares of Galectin, if you have information or would like to learn more about these claims, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Casey Sadler, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, by toll-free telephone at (888) 773-9224 or by telephone at (310) 201-9150, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.